Table 1.
Clinical characteristics of all 18 HCT patients including the number of blood samples and stools samples collected from each patient
| PT # | Age/Sex | Conditioning | Intensity | Type | Manipulation | Underlying diagnosis | Neutrophil reconstitution day | # Stool samples | # Blood samples | Prophylactic antibiotics | Treatment antibiotics |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 48M | Busulfan, cy, thiotepa | MA | Auto | n/a | Diffuse large B cell lymphoma | 6 | 9 | 6 | cipro (IV/PO) | pip-tazo (IV) |
| 2 | 48M | BCNU, etoposide, cytarabine melphalan | MA | Auto | n/a | Diffuse large B cell lymphoma | 7 | 10 | 7 | cipro (IV/PO) | pip-tazo (IV) |
| 3 | 72F | BCNU, etoposide, cytarabine, melphalan | MA | Auto | n/a | Mantle cell lymphona | 8 | 22 | 4 | cipro (IV/PO) | metro (IV/PO), pip-tazo (IV), vanco (PO) |
| 4 | 72M | fludarabine/melphalan | RIC | Allo | unmodified | Myelodysplastic syndrome | 14 | 22 | 7 | cipro (IV), TMP-SMX (PO) | mero (IV), pip-tazo (IV), vanco (IV) |
| 5 | 57M | TBI, thiotepa, cy | MA | Allo | T-cell depleted | Acute lymphoblastic leukemia | 7 | 23 | 5 | cipro (PO), vanco (IV), TMP-SMX (PO) | cefepime (IV) |
| 6 | 40M | TBI, thiotepa, cy, fludarabine | RIC | Allo | unmodified | Acute lymphoblastic leukemia | 9 | 19 | 6 | ceftriaxone (IV), vanco (IV) | pip-tazo (IV) |
| 7 | 57M | TBI, thiotepa, cy, fludarabine | MA | Allo | T-cell depleted | Acute myeloid leukemia | 7 | 23 | 6 | cipro (IV), vanco (IV) | pip-tazo (IV) |
| 8 | 70F | Fludarabine/melphalan | RIC | Allo | unmodified | Myelofibrosis | 9 | 14 | 5 | cipro (IV), vanco (IV) | none |
| 9 | 51M | TBI, Fludarabine, cy | RIC | Allo | unmodified | Aplastic anemia | 19 | 22 | 4 | cipro (PO), vanco (IV), TMP-SMX (PO) | pip-tazo (IV) |
| 10 | 69F | TBI, cy, thiotepa, fludarabine | RIC | Allo | unmodified | T-cell lymphoma | 9 | 18 | 5 | cipro (PO), vanco (IV) | none |
| 11 | 47F | TBI, thiotepa, cy | MA | Allo | T-cell depleted | Acute lymphoblastic leukemia | 6 | 23 | 6 | cipro (PO), vanco (IV), TMP-SMX (PO) | cefepime (IV), metro (IV), pip-tazo (IV) |
| 12 | 66M | Fludarabine/melphalan | RIC | Allo | unmodified | Chronic lymphocytic leukemia | 7 | 11 | 5 | cipro (PO), vanco (IV) | none |
| 13 | 62M | Fludarabine/melphalan | RIC | Allo | unmodified | Multiple myeloma | 6 | 13 | 9 | cipro (PO), vanco (IV), TMP-SMX (PO) | cefazolin (IV) |
| 14 | 56M | Fludarabine/melphalan | RIC | Allo | unmodified | Mantle cell lymphona | 10 | 20 | 5 | atova (PO), cipro (IV), vanco (IV) | none |
| 15 | 49F | BCNU, etoposide, cytarabine melphalan | MA | Auto | n/a | Diffuse large B cell lymphoma | 8 | 16 | 5 | cipro (PO), vanco (IV) | pip-tazo (IV) |
| 16 | 63F | Fludarabine/melphalan | RIC | Allo | unmodified | Classic Hodgkins lymphoma | 10 | 18 | 8 | cipro (PO), vanco (IV) | pip-tazo (IV), vanco (IV) |
| 17 | 75F | Fludarabine/melphalan | MA | Allo | unmodified | Acute myeloid leukemia | 13 | 16 | 7 | atova (PO), cipro (IV), vanco (IV) | linezolid (IV), mero (IV), pip-tazo (IV) |
| 18 | 55M | bu, mel, flu | MA | Allo | T-cell depleted | Myelodysplastic syndrome | 8 | 19 | 6 | ciprofloxacin (IV), TMP-SMX (PO), vanco (IV) | pip-tazo (IV), vanco (IV) |
Pt, patient; Auto, autologous; Allo, allogeneic; RIC, reduced intensity conditioning; MAC, myeloablative conditioning; DLBCL, diffuse large B cell lymphoma; MDS, myelodysplastic syndrome; CLL, chronic lymphocytic leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; IV, intravenous; PO, oral; cipro, ciprofloxacin; metro, metronidazole; pip-tazo, piperacillin-tazobactam; mero, meropenem; vanco, vancomycin; TMP-SMX, trimethoprim-sulfamethoxazole.